Compositions comprising satiety peptides (e.g., PYY, PYY(3-36), GLP-1, oxyntomodulin, and cholecystokinin) and DPP-IV inhibitors and methods of treating metabolic diseases with such compositions are provided.

Compositions comprising satiety peptides (e.g., PYY, PYY(3-36), GLP-1, oxyntomodulin, and cholecystokinin) and DPP-IV inhibitors and methods of treating metabolic diseases with such compositions are provided.

Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyrl residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyrl residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

There is provided a method for treating or reducing an anticancer agent-induced nephrotoxic injury, the method comprising the step of administering a Y1 receptor activator in an amount effective to treat or reduce the anticancer agent-induced nephrotoxic injury in a subject. Further, there is provided a method for screening an agent for treating or reducing an anticancer agent-induced nephrotoxic injury, the method comprising (a) applying a candidate material to a test sample of renal tissues or cells; and (b) identifying a Y1 receptor signaling in the test sample of renal tissues or cells.

The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide Y as an active ingredient. The neuropeptide Y according to the present invention reduces the expression of a cell adhesion factor in osteoblasts in which a Y1 receptor is present, and consequently an effect of releasing a haematopoietic stem cell from bone marrow into the blood is excellent. When a haematopoietic stem cell is released into the blood, the number of osteoclasts which induce an osteoporotic lesion by differentiation from the haematopoietic stem cell decreases, and thus progression of a bone erosion caused by osteoclasts can be prevented. Accordingly, the neuropeptide Y which is an active ingredient of the composition of the present invention is useful as a therapeutic agent for osteoporosis.

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

A centrally-acting peptide derivative, including a centrally-acting portion, a cell-penetrating sequence portion, and an endosomal-escape portion.

The present disclosure relates to the use of intranasal neuropeptide Y (NPY) analogs having D-amino acids, such as [D.sup.26-His]-NPY: (1) for early intervention to prevent or (2) to treat, to reverse, or reduce symptoms of stress-related impairments such as PTSD, depression, substance abuse, and/or memory deficits following exposure to traumatic or surgical stress.